Erste Erfahrungen zur Akzeptanz der HPV-Impfung

Bertz J, Giersiepen K, Haberland J et al (2006) Krebs in Deutschland, 5. überarbeitete, aktualisierte Aufl. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI, Saarbrücken Brown DR, Shew ML, Qadadri B et al (2005) A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191:182–192 Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943 Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18. Lancet 367:1247–1255 Harper D, Gall S, Naud P et al (2008) Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long term follow up through 6.4 years in women vaccinated with Cervarix™. Gynecol Oncol 109:158–159 Heßling A (2006) Jugendsexualität. Wiederholungsbefragung von 14- bis 17-Jährigen und ihren Eltern, Ergebnisse der Repräsentativbefragung 2005. Bundeszentrale für gesundheitliche Aufklärung, BZgA, Köln Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574):1693–1702 Mao C, Koutsky LA, Ault KA et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neuplasia: a randomized controlled trial. Obstet Gynecol 107:18–27 Munoz N, Bosch FX, Sanjose S de et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527 Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108 Schreckenberger C, Kaufmann AM, Schneider A (2007) Implementierung der HPV-Impfung. Dtsch Med Wochensch 132:2221–2224 Schwarz T, Leo O (2008) Immune response to human papillomavirus after prohpylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 110:S1–S10 Schwarz T, Spaczynski M, Schneider A et al (2009) Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine 27(4):581–587 Stanley M, Lowy D, Frazer I (2006) Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24S3:S3/106–S3/113 Villa LL, Costa RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278 Villa LL, Ault KA, Guiliano AR et al (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus types 6,11,16 and 18, Vaccine 24(27–28):5571–5583 Villa LL, Costa RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus like particle vaccine through 5 years follow up. Br J Cancer 95:1459–1466 Walboomers JM, Jacobs MV, Mano MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12 Zur Hausen H (2002) Papillomavirues and cancer from basic studies to clinical application. Nat Rev Cancer 2(5):342–350